Hypothesis

A short course of mTOR inhibition (e.g., rapamycin) administered before intermittent senolytic dosing will selectively suppress the early, pro‑fibrotic SASP while leaving later reparative SASP components intact, thereby reducing fibrosis and off‑target toxicity compared with senolytic monotherapy.

Rationale

SASP evolves from an early phase rich in IL‑1α, TGF‑β, and matrix‑remodeling factors that support tissue repair to a chronic phase dominated by IL‑6, IL‑8, and IL‑1β that drives inflammation and fibrosis[1]. mTOR inhibitors blunt IL‑1α translation, curtailing the upstream trigger for both early pro‑fibrotic signals and the downstream inflammatory amplification loop[1]. Senolytics such as ABT‑263 clear senescent cells but cause thrombocytopenia due to shared Bcl‑2 family dependencies in platelets and senescent cells[2]. By damping the early SASP first, we hypothesize that the microenvironment becomes less permissive for fibroblast activation and platelet‑senescent cell interactions, lowering the effective senolytic dose needed for clearance and reducing hematologic side effects.

Predictions

1. In aged mice with induced liver fibrosis, rapamycin pretreatment (3 days) followed by a single low‑dose ABT‑263 pulse will yield lower hydroxyproline content and improved liver function tests than ABT‑263 alone.
2. Plasma levels of early SASP mediators (IL‑1α, TGF‑β1) will drop after rapamycin, while later SASP cytokines (IL‑6, IL‑8) will remain detectable, indicating selective modulation.
3. Platelet counts will show <10 % decline in the combination group versus >30 % decline with ABT‑263 monotherapy, reflecting reduced off‑target toxicity.
4. Histology will reveal less activated stellate cell (α‑SMA) accumulation without loss of proliferative Ki‑67‑positive hepatocytes, suggesting preservation of reparative capacity.

Experimental Design

• Animals: 20‑month‑old C57BL/6 mice treated with carbon tetrachloride (CCl₄) twice weekly for 6 weeks to establish fibrosis.
• Groups (n = 10 each): vehicle, rapamycin alone (1 mg/kg i.p. qd × 3), ABT‑263 alone (50 mg/kg p.o. single dose), rapamycin → ABT‑263 (rapamycin regimen then ABT‑263 2 h after last rapamycin).
• Readouts (collected 48 h post‑ABT‑263): serum ALT/AST, platelet count, plasma cytokine panel (IL‑1α, IL‑6, IL‑8, TGF‑β1), liver hydroxyproline, immunohistochemistry for α‑SMA, Senescent‑associated β‑gal, and Ki‑67.
• Statistical plan: One‑way ANOVA with Tukey post‑hoc; power analysis assumes 30 % effect size, α = 0.05, power = 0.8.

Potential Outcomes and Interpretation

If the combination group shows reduced fibrosis and platelet sparing alongside a dissociated SASP profile (low early, preserved late), the hypothesis is supported, indicating that temporally targeted senomorphic priming can widen the therapeutic window of senolytics. Conversely, if fibrosis improves only with ABT‑263 monotherapy or platelet toxicity remains unchanged, the hypothesis is refuted, suggesting that early SASP suppression does not sufficiently modulate senolytic off‑target effects or that compensatory pathways sustain fibroblast activation. Either outcome will clarify whether SASP timing can be leveraged to achieve selective senescent cell clearance without compromising tissue repair.